Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 GeneticVariation disease BEFREE Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma. 29373711 2018
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer. 28008156 2017
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE TIMP1, HMGB3, CLDN1, CDK1 and PPARG as well as pathways of Cell cycle, Citrate cycle, and Oxidative phosphorylation may play important roles in the progression of thyroid carcinoma. 27268919 2016
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Compared with RAS or PAX8/PPARG-positive TCs, BRAFV600E or RET/PTC-positive TCs were more often associated with stage III/IV disease (40% vs 15%, P < 0.001) and recurrence (10% vs 0.7%, P < 0.001; mean follow-up 33 ± 21 mo). 26258321 2015
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall. 24811481 2014
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE The PPAR-γ agonist pioglitazone is highly therapeutic in a transgenic mouse model of PPFP-positive thyroid carcinoma, suggesting that PPAR-γ agonists might be beneficial in patients with PPFP-positive thyroid carcinomas. 25069464 2014
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 GeneticVariation disease BEFREE RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. 23436219 2013
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE TSH receptor mRNA reverse transcription-polymerase chain reaction, the Veracyte and Asuragen commercial methods, and the noncommercial use of BRAF, RAS, RET/PTC, and PAX8/PPARγ testing have promising roles in the diagnosis and treatment of patients with nodular thyroid disease and thyroid cancer. 22984796 2013
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 GeneticVariation disease BEFREE Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases. 23738683 2013
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 GeneticVariation disease BEFREE Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements. 21878896 2011
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 GeneticVariation disease BEFREE The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs). 19147628 2009
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 GeneticVariation disease BEFREE As such, this article addresses the following aspects of intragenic mutations in thyroid cancer: thyroid stimulating hormone receptor and guanine-nucleotide-binding proteins of the stimulatory family mutations in hyperfunctioning tumors; mutations in RAS and other genes and aneuploidy; PAX8-PPARgamma rearrangements; BRAF mutations; mutations in oxidative phosphorylation and Krebs cycle genes in Hürthle cell tumors; mutations in succinate dehydrogenase genes in medullary carcinoma and C-cell hyperplasia; and mutations in TP53 and other genes in poorly differentiated and anaplastic carcinomas. 18502330 2008
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 GeneticVariation disease BEFREE Here, we report our discovery of a novel CREB3L2-PPARgamma fusion mutation in thyroid carcinoma with t(3;7)(p25;q34), showing that a family of somatic PPARgamma fusion mutations exist in thyroid cancer. 18757431 2008
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 GeneticVariation disease BEFREE The common somatic genetic changes in thyroid cancer of follicular cell origin (RET/PTC, NTRK, RAS, BRAF, PAX8-PPARgamma) are generally mutually exclusive, with distinct genotype-histologic subtype of thyroid cancer and genotype-phenotype associations observed. 18043251 2008
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Using this mutant mouse, we tested the hypothesis that the peroxisome proliferator-activated receptor gamma (PPARgamma) could function as a tumor suppressor in thyroid cancer in vivo. 16314832 2006
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Rosiglitazone is a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist that has been shown to induce differentiation, cell cycle arrest, and apoptosis in a variety of human cancers including thyroid cancer. 17188145 2006
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Therapeutic disease CTD_human Our investigations document that human thyroid cancer cell lines commonly express PPARgamma, but chromosomal translocations involving PPARgamma are uncommon. 15785241 2005
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 AlteredExpression disease BEFREE Our investigations document that human thyroid cancer cell lines commonly express PPARgamma, but chromosomal translocations involving PPARgamma are uncommon. 15785241 2005
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE These data identify several differentially expressed genes, such as FGD3, that may serve as potential targets of PPARgamma and as members of novel molecular pathways involved in the development of thyroid carcinomas. 15972966 2005
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Absence of a PAX-8/PPAR-gamma fusion gene in the series of 68 thyroid samples is in agreement with the suggestion of PAX-8/PPAR-gamma rearrangement being restricted to a subset of follicular thyroid cancers. 16187907 2005
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE The objectives of the present work were: to study and compare the relative expression of PPARgamma in normal, benign and malignant thyroid tissues and to correlate PPARgamma immunostaining with clinical/pathological features of patients with thyroid cancer. 15238980 2004
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Taken together, these results suggest that PPARgamma agonist inhibit cell growth of some types of human thyroid cancer. 11344222 2001
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE The experiments demonstrate an oncogenic role for PPARgamma and suggest that PAX8-PPARgamma1 may be useful in the diagnosis and treatment of thyroid carcinoma. 10958784 2000